This site is intended for healthcare professionals
Drug information

Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion

Read time: 35 mins
Last updated: 15 Sep 2020
Published: 15 Sep 2020

4.1 Therapeutic indications

Cyclophosphamide may be used alone or in combination with other chemotherapeutic agents, depending on the indication. Cyclophosphamide is indicated in the treatment of:

• Chronic Lymphocytic Leukemia (CLL)

• Acute Lymphocytic Leukemia (ALL)

• As conditioning for a bone marrow transplantation, in the treatment of Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia, in combination with whole body irradiation or busulfan.

• Hodgkin's lymphoma, Non-Hodgkin's lymphoma and Multiple Myeloma

• Metastatic ovarian, and breast, carcinoma

• Adjuvant treatment of breast carcinoma

• Ewing's sarcoma

• Small cell lung cancer

• Advanced or metastatic neuroblastoma,

• Life-threatening autoimmune diseases: severe progressive forms of lupus nephritis and Wegener's granulomatosis.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).